HC Wainwright Initiates Coverage on Mural Oncology (NASDAQ:MURA)

Research analysts at HC Wainwright began coverage on shares of Mural Oncology (NASDAQ:MURA) in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage set a “buy” rating and a $18.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 383.87% from the stock’s current price.

MURA has been the subject of a number of other reports. Rodman & Renshaw assumed coverage on shares of Mural Oncology in a report on Friday, June 28th. They set a “buy” rating and a $15.00 price objective for the company. Raymond James started coverage on shares of Mural Oncology in a research note on Friday, October 4th. They set a “strong-buy” rating and a $18.00 price target for the company.

Mural Oncology Trading Up 7.8 %

NASDAQ MURA opened at $3.72 on Thursday. The business has a fifty day simple moving average of $3.26 and a 200 day simple moving average of $3.45. The firm has a market capitalization of $62.96 million and a P/E ratio of -0.36. Mural Oncology has a 12 month low of $2.88 and a 12 month high of $17.00.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, August 13th. The company reported ($1.86) EPS for the quarter, beating analysts’ consensus estimates of ($1.90) by $0.04. As a group, sell-side analysts predict that Mural Oncology will post -7.47 EPS for the current fiscal year.

Institutional Trading of Mural Oncology

A number of institutional investors have recently bought and sold shares of MURA. BBR Partners LLC purchased a new position in shares of Mural Oncology in the 2nd quarter worth about $31,000. Rhumbline Advisers acquired a new stake in shares of Mural Oncology in the second quarter valued at approximately $34,000. Canada Pension Plan Investment Board acquired a new position in Mural Oncology during the 2nd quarter valued at about $70,000. Dimensional Fund Advisors LP acquired a new stake in Mural Oncology in the 2nd quarter valued at about $71,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Mural Oncology during the second quarter worth $84,000. 80.21% of the stock is currently owned by hedge funds and other institutional investors.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.